RxDoctor Payments Data

Daniel Goodman, MD

Internal Medicine · Atlanta, GANPI 1710901640

Payments from drug & device makers

$2,042in general payments, 2019–2025

Across 125 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$419
  • Amgen$314
  • Johnson & Johnson$301
  • Pfizer$179
  • Merck$115
  • Lilly USA, LLC$109
  • plus $605 from 15 others

What the payments were for

  • Food & beverage$2,02599%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,042 in reported general payments places this provider in the 75th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$353,078
Medicare patients
436
Services billed
8,246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban152$198,306
TrulicityDulaglutide142$166,899
ProliaDenosumab64$109,221
FarxigaDapagliflozin Propanediol87$101,069
Trelegy ElliptaFluticasone/Umeclidin/Vilanter85$78,308
OzempicSemaglutide59$72,396
Repatha SureclickEvolocumab71$71,528
MounjaroTirzepatide50$58,053
JardianceEmpagliflozin41$54,794
XareltoRivaroxaban20$27,554
Stiolto RespimatTiotropium Br/Olodaterol Hcl31$20,572
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr30$16,744
Praluent PenAlirocumab21$14,909
Breo ElliptaFluticasone/Vilanterol19$12,927
Atorvastatin Calcium1,139$8,725

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$109$224,952192 claims
PfizerEliquis$179$198,306152 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Shingrix, Incruse Ellipta$27$118,358178 claims
AmgenProlia$314$109,22164 claims
AstraZenecaFarxiga, Symbicort$419$104,843101 claims
Boehringer IngelheimJardiance, Stiolto Respimat$89$75,36772 claims
Novo NordiskOzempic$96$72,39659 claims
Johnson & JohnsonXarelto$301$27,55420 claims
AbbVieSynthroid$108$6,29361 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →